• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Onconova Therapeutics, Inc - Product Pipeline Review - H2 2011 Product Image

Onconova Therapeutics, Inc - Product Pipeline Review - H2 2011

  • ID: 1943813
  • October 2011
  • 101 pages
  • Global Markets Direct

Onconova Therapeutics, Inc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Onconova Therapeutics, Inc - Product Pipeline Review - H2 2011” provides data on the Onconova Therapeutics, Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Onconova Therapeutics, Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from Onconova Therapeutics, Inc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Onconova Therapeutics, Inc - Brief Onconova Therapeutics, Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Onconova Therapeutics, Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Onconova Therapeutics, Inc Snapshot
Onconova Therapeutics, Inc Overview
Key Information
Key Facts
Onconova Therapeutics, Inc – Research and Development Overview
Key Therapeutic Areas
Onconova Therapeutics, Inc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Onconova Therapeutics, Inc – Pipeline Products Glance
Onconova Therapeutics, Inc Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Onconova Therapeutics, Inc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Onconova Therapeutics, Inc – Drug Profiles
Estybon + Irinotecan
Product Description
Mechanism of Action
R&D Progress
Ex-RAD
Product Description
Mechanism of Action
R&D Progress
ON 123 Series
Product Description
Mechanism of Action
R&D Progress
ON 123300
Product Description
Mechanism of Action
R&D Progress
ON 128060
Product Description
Mechanism of Action
R&D Progress
ON 24160
Product Description
Mechanism of Action
R&D Progress
Onconova Therapeutics, Inc – Pipeline Analysis
Onconova Therapeutics, Inc – Pipeline Products by Therapeutic Class
Onconova Therapeutics, Inc - Pipeline Products By Target
Onconova Therapeutics, Inc – Pipeline Products by Route of Administration
Onconova Therapeutics, Inc – Pipeline Products by Molecule Type
Onconova Therapeutics, Inc – Recent Pipeline Updates
Onconova Therapeutics, Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 28, 2008: Onconova Therapeutics Announces Positive Phase I Results For Its Lead Anticancer Compound ON 01910.Na
Sep 27, 2010: Onconova Presents New Data Demonstrating Radioprotection By Ex-RAD At Radiation Research Society Annual Meeting
Jul 26, 2004: Onconova Therapeutics Initiates Phase I Clinical Trial Of Anti-Cancer Agent ON 01910.Na
Jan 23, 2009: Onconova And DoD Collaborators Publish Research Demonstrating Increased Survivability Of Previously Lethal Radiation In Mice With Ex-RAD
Jan 23, 2009: Onconova Therapeutics Announces Initiation Of Phase I ClinicalTesting For Ex-RAD, A Radioprotective Drug
Apr 21, 2009: Onconova Therapeutics Announces Presentation Of Nonclinical Data On Lead Compound ON 01910.Na And New Jak 2/Bcr-abl Inhibitors At AACR
Apr 21, 2009: Onconova Therapeutics Announces Presentation Of Nonclinical Data On Lead Compound ON 01910.Na At AACR
Apr 16, 2007: Onconova Presents Clinical And Non-Clinical Results Of ON 01910.Na At American Association Of Cancer Research Conference
Apr 11, 2008: Onconova Therapeutics Announces Presentation Of Clinical And Nonclinical Data On Lead Compound On 01910.Na At AACR
Dec 07, 2009: Onconova Therapeutics Announces Presentation of Clinical Proof of Concept of ON 01910.Na in Patients with High Risk Myelodysplastic Syndrome (MDS) at ASH 2009 Annual Meeting
Jun 06, 2011: Onconova Highlights Positive Data From Phase I Study Of Estybon In Advanced Pancreatic Cancer At ASCO Annual Meeting
Jun 06, 2011: Onconova Highlights Positive Data Of ESTYBON In Solid Tumors At ASCO Annual Meeting
Jun 06, 2011: Onconova To Intitate Phase II/III Study Of ESTYBON For Pancreatic Cancer
Jun 05, 2006: Onconova Therapeutics Presented Data On Anti-Cancer Compound ON 01910.Na at American Society of Clinical Oncology (ASCO) Conference
Oct 04, 2010: Onconova Receives FDA Special Protocol Assessment For Pivotal Phase III Trial Of Estybon In Myelodysplastic Syndromes
Dec 03, 2010: Onconova To Present Clinical Trials Update For Estybon At ASH Annual Meeting
Jun 01, 2010: LLS And Onconova Form Partnership To Advance Clinical Development Of ESTYBON In High Risk MDS Patients
Financial Deals Landscape
Onconova Therapeutics, Inc, Deals Summary
Onconova Therapeutics, Inc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Onconova Therapeutics Secures $11.69 Million In Venture Financing
Onconova Therapeutics Secures $6.55 Million In Venture Financing
Partnerships
The Leukemia & Lymphoma Society Enters Into An Agreement With Onconova Therapeutics
KINAXO Biotechnologies Enters Into An Agreement With Onconova Therapeutics
Licensing Agreements
Onconova Therapeutics Enters Into Licensing Agreement With SymBio Pharmaceuticals For Rigosertib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos